Venetoclax monotherapy leads to durable responses in R/R chronic ...

Venetoclax Monotherapy Shows Deep, Durable Responses in R/R ...

Treatment with venetoclax appeared to improve responses in patients with relapsed or refractory chronic lymphocytic leukemia, according to ...

Venetoclax Monotherapy Leads to Durable Responses in Relapsed ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell ...

Venetoclax monotherapy leads to durable responses in R/R chronic ...

These data demonstrate deep and durable responses with venetoclax monotherapy in patients with R/R CLL, including BCRi-pretreated patients, ...

Venetoclax Monotherapy Leads to Responses, Genomic ... - OncLive

Venetoclax Monotherapy Leads to Responses, Genomic Changes in R/R CLL ... Treatment with venetoclax (Venclexta) monotherapy elicited durable ...

Activity of venetoclax in patients with relapsed or refractory chronic ...

No new safety signals were identified. Interpretation. These data demonstrate deep and durable responses with venetoclax monotherapy in patients ...

Long-term Follow-up of Patients with Relapsed or Refractory Non ...

We have previously reported that targeting BCL-2 with venetoclax in relapsed/refractory (R/R) NHL was well tolerated as monotherapy, leading to an overall ...

Venetoclax Monotherapy Demonstrates Deep, Durable Responses ...

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL ... chronic lymphocytic leukemia: analysis of ...

Venetoclax Elicits Enduring Responses in R/R Chronic Lymphocytic ...

“This phase 3b trial VENICE-1 indicates venetoclax monotherapy can have deep and durable responses in patients with relapsed or refractory ...

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is ...

Key Points. Patients with relapsed CLL achieving complete remission or undetectable MRD on venetoclax treatment have the most durable responses. Less durable ...

Venetoclax Produces Lasting Responses in Relapsed/Refractory CLL

“This phase 3b trial VENICE-1 indicates venetoclax monotherapy can have deep and durable responses in patients with relapsed or refractory ...

Venetoclax/Rituximab Retreatment Produces Durable Responses in ...

... chronic lymphocytic leukemia (R/R CLL). Hemasphere. 2023;7(suppl):e492813f. doi:10.1097/01.HS9.0000967716.49281.3f. Advertisement. News.

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell ...

We demonstrate long-term durable responses and acceptable toxicity profile of venetoclax-ibrutinib in R/R MCL and show feasibility of ...

Update on the management of relapsed/refractory chronic ... - Nature

In a pooled analysis of 347 patients with RR CLL receiving 400 mg Ven monotherapy, additional factors associated with shorter durability of ...

Venetoclax–Rituximab in Relapsed or Refractory Chronic ...

Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic ...

Durable Response to Venetoclax Monotherapy in Richter's Syndrome

CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma. In March 2017, she was started on the first round of R-CHOP chemotherapy, which was ...

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow ...

24 This recommendation is based on the phase 3 study of venetoclax+rituximab in R/R CLL (MURANO trial), where durable responses after 2 years of ...

Assessment of the Efficacy of Therapies Following Venetoclax ...

... venetoclax appear to be the most effective strategies with durable responses. ... venetoclax monotherapy for patients with relapsed/refractory chronic ...

Addition of rituximab in relapsed/refractory chronic lymphocytic ...

Despite the durable responses that can be achieved by venetoclax with rituximab in the R ... durable responses to venetoclax monotherapy. These ...

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic ...

Ibrutinib monotherapy is effective in CLL and leads to rapid ... MRD response for venetoclax monotherapy in del(17p) CLL was reported ...

Real-world outcomes and management strategies for venetoclax ...

Venetoclax is an oral second-generation BCL2 inhibitor with demonstrated activity and durable responses in relapsed/refractory (R/R) chronic ...